BAGSVÆRD, DENMARK--(Marketwire - June 16, 2008) - Significant weight loss sustained in obese people treated with liraglutide for one year
Novo Nordisk today announced clinical results from a 32-week open-label extension of a 20-week phase 2 obesity study, in which treatment with liraglutide, the once-daily human GLP-1 analogue, was tested in obese people without diabetes. Novo Nordisk reported headline results from the initial 20 weeks of the phase 2 study in November 2007.
